Healthcare
Nuvation Bio Inc.(NUVB-WT)
Live Price
Offline$0.0763
-4.16% today
Window Change
-69.53%
Window
Jun 25, 2025 โ May 14, 2026
- Market Cap
- $26.15M
- Revenue Growth
- +699.0%
- EPS Growth
- +71.6%
- Dividend Yield
- 0.0%
Coverage: 224 bars ยท Jun 25, 2025 โ May 14, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nuvation Bio Inc. (NUVB-WT) is a Healthcare stock with a market cap of $26.15M and listed on NYSE. The stock last traded around $0.08 and down 69.5% across the available one-year price window (Jun 25, 2025 โ May 14, 2026). Baseline metrics include revenue growth of +699.0%, EPS growth of +71.6%, a dividend yield of 0.0%. What stands out right now is revenue +699.0%, EPS +71.6%, free cash flow -33.1% with operating margin -338.7% and ROIC -41.0%. Valuation already assumes a fairly strong business story at price/sales 24.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines NUVB-WT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+699.0% vs +7.6% peer median
Operating Margin
Below sector median
-338.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Mar 2, 2026 with an EPS surprise of -22.3% and a revenue surprise of +12.2%.
The operating story is still moving forward
Revenue is running at +699.0% and EPS at +71.6%, with operating margin around -338.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -25.8% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 2, 2026 | -22.3% | -27.0% | -21.1% | -26.4% |
2025 Nov 3, 2025 | +3.4% | -19.5% | -33.0% | +40.9% |
2025 Aug 7, 2025 | -1.9% | -13.9% | -23.4% | -19.1% |
Benchmark Edge
NUVB-WT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NUVB-WT
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NUVB-WT Max Drawdown
-92.14%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NUVB-WT and SPY.
Company Overview
Nuvation Bio Inc.
New York Stock Exchange
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
- Leadership
- David T. Hung
- IPO Date
- Aug 26, 2020
- Employees
- 220
- Street Address
- 1500 Broadway, Suite 1401
- Mailing
- New York, NY, 10036
- Region
- New York, NY, US
- Reporting Currency
- USD
- Investor Line
- +1 646 616 2000
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 24.7
- Price/Book
- 5.1
Growth
- Revenue
- +699.0%
- EPS
- +71.6%
- Free Cash Flow
- -33.1%
Profitability
- Gross Margin
- 86.6%
- Operating Margin
- -338.7%
- Net Margin
- -325.3%
- ROE
- -57.5%
- ROIC
- -41.0%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 6.95
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.